Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02816697 · ClinicalTrials.gov registry record · NA
Implementation of a System-level Tobacco Treatment Intervention
A NA study of Lung Cancer and Smoking Cessation, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 263
- Enrollment target
- 2
- Study locations
NCT02816697: Active NA study of Lung Cancer and Smoking Cessation, sponsored by Dana-Farber Cancer Institute.
NCT02816697 is a NA study of Lung Cancer and Smoking Cessation that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 263 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02816697, a NA study of Lung Cancer and Smoking Cessation, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 263 participants
- Enrollment target
- 2
- Study locations
Study Summary
The proposed study plans to adapt and study the implementation and effectiveness of integrating Clinical and Community Effort Against Secondhand smoke Exposure (CEASE) into the thoracic oncology setting using mixed methods.
Primary Outcome
Biochemical verification of smoking cessation
Conditions Studied
Interventions
- OTHER CEASE
- OTHER Usual Care Tobacco Treatment Services
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2016-06 |
| Est. Completion | 2026-02 |
| Phase | NA |
What the registry record for NCT02816697 still lists
NCT02816697 is an interventional study that assigns participants to a tested intervention. The registered 263 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which CEASE is the first listed.
NCT02816697 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02816697 about?
NCT02816697 is a clinical study titled "Implementation of a System-level Tobacco Treatment Intervention". The proposed study plans to adapt and study the implementation and effectiveness of integrating Clinical and Community Effort Against Secondhand smoke Exposure (CEASE) into the thoracic oncology setting using mixed methods.
What is the current status of trial NCT02816697?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 263 participants. The study started on 2016-06. Estimated completion is 2026-02.
What conditions does trial NCT02816697 study?
This clinical trial studies the following conditions: Lung Cancer, Smoking Cessation.
What interventions are being tested in trial NCT02816697?
The interventions under investigation include: CEASE (OTHER), Usual Care Tobacco Treatment Services (OTHER).
Who is sponsoring clinical trial NCT02816697?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02816697 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02816697's enrollment target sits among peer trials
263 111th of 409 higher than 299 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04067336 · 263 participants · Phase 1
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- NCT06234423 · 263 participants · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- NCT06724627 · 263 participants · NA
Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia